<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01368627</url>
  </required_header>
  <id_info>
    <org_study_id>Version 2.0</org_study_id>
    <nct_id>NCT01368627</nct_id>
  </id_info>
  <brief_title>The E-SERIES Registry for Supralimus® Coronary Stent for the Treatment of Unselected Patients With Coronary Lesions</brief_title>
  <official_title>A Prospective, Multinational Investigation of the Supralimus® Sirolimus-Eluting Stent for the Treatment of Unselected Patients With Coronary Lesions in the &quot;Real- World&quot; Clinical Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sahajanand Medical Technologies Pvt. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cardiovascular Research Center, Brazil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sahajanand Medical Technologies Pvt. Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      E-SERIES Registry evaluate the procedural and clinical outcomes of the Supralimus® SES in the
      treatment of unselected, high risk patients having coronary Artery blockage in the real world
      clinical practice.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      E-SERIES Registry is Prospective, multinational (Asia, South America and Europe),
      non-randomized, post-marketing web-based registry.

      For this Study Up to 100 clinical sites in Asia, South America and Europe. Patients &quot;ALL
      COMERS&quot; assigned for percutaneous coronary interventions who present with at least one
      angiographically documented coronary artery lesion suitable for percutaneous treatment with
      the Supralimus® SES.

      All subjects who provided signed informed consent prior to procedure, and have at least one
      lesion in a major epicardial vessel or major branch (&gt;2.25mm), and are suitable for
      percutaneous treatment including stenting procedure with the Supralimus® SES. There are no
      limit regarding the number of lesions and/or study stents to be used, and stenting technique
      will be left at the operator's discretion; however, it is recommended according to the BEST
      interventional practice according to the current guidelines.

      All patients will undergo follow-up clinical evaluation at 1, 6, 12 and 24 months.
      Angiographic follow-up will be performed at 6 months in a subset of high risk lesions
      including bifurcations (first 100 lesions) and left main stem (first 100 lesions).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MAJOR ADVERSE CARDIAC EVENTS (MACE)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rates of procedural success</measure>
    <time_frame>24 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of Major Adverse Cardiac Event (MACE)</measure>
    <time_frame>In-hospital, 30 days, 6 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of target lesion revascularization (TLR)</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of stent thrombosis (acute, sub-acute, late and very-late)</measure>
    <time_frame>Up to 24 months follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1274</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Supralimus® Sirolimus-Eluting Coronary Stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Supralimus® Sirolimus-Eluting Coronary Stent</intervention_name>
    <description>Supralimus® Coronary Stent System consisting of the MATRIX® Coronary Stent having Sirolimus eluting from Biodegradable Polymeric Matrix on a Stainless Steel Platform, Drug concentration 1.4 µg/mm2</description>
    <arm_group_label>Supralimus® Sirolimus-Eluting Coronary Stent</arm_group_label>
    <other_name>Drug Eluting Stent (DES)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. CLINICAL INCLUSION CRITERIA: Patients &gt;18 years, clinical indication for elective or
             emergency percutaneous coronary intervention with stent implantation of at least one
             angiographically documented coronary artery lesion; agreement to undergo ALL study
             protocol follow-ups.

          2. ANGIOGRAPHIC INCLUSION CRITERIA: Diseased coronary vessels with at least one lesion
             with ≥50% diameter stenosis by visual estimation in a major epicardial vessel or a
             major branch (&gt;2.25mm) with anatomy suitable for percutaneous treatment with the
             Supralimus SES.

        Exclusion Criteria:

          1. CLINICAL EXCLUSION CRITERIA: Known illness with life expectancy &lt;12 months;
             impossibility to comply with all protocol follow-ups.

          2. ANGIOGRAPHIC EXCLUSION CRITERIA: Anatomy unsuitable for percutaneous treatment with
             implantation of the Supralimus SES.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandre Abizaid,, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Dante Pazzanese de Cardiologia São Paulo, SP, Brazil</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CIAS- Unimed Vitória</name>
      <address>
        <city>Vitória</city>
        <state>Espírito Santo</state>
        <zip>29047-575</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Cardiologia e Radiologia</name>
      <address>
        <city>Goiânia</city>
        <state>Goiás</state>
        <zip>74823-320</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Luxemburgo</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <zip>30380-090</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Monte Sinai</name>
      <address>
        <city>Juiz de Fora</city>
        <state>Minas Gerais</state>
        <zip>36025-550</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vita</name>
      <address>
        <city>Curitiba</city>
        <state>Paraná</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H.C.Unesp</name>
      <address>
        <city>Botucatu</city>
        <state>Sao Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital São Camilo</name>
      <address>
        <city>São Paulo</city>
        <zip>05022-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2011</study_first_submitted>
  <study_first_submitted_qc>June 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2011</study_first_posted>
  <last_update_submitted>August 22, 2012</last_update_submitted>
  <last_update_submitted_qc>August 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Restenosis</keyword>
  <keyword>Stent thrombosis</keyword>
  <keyword>Coronary stents</keyword>
  <keyword>Angioplasty</keyword>
  <keyword>Drug Eluting Stents(DES)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

